key: cord-0258233-ps53t1px authors: Shrestha, L.; Lin, M. J.; Xie, H.; Mills, M. G.; Bakhash, S. A. M.; Gaur, V. P.; Livingston, R. J.; Castor, J.; Bruce, E. A.; Botten, J. W.; Huang, M.-L.; Jerome, K. R.; Greninger, A. L.; Roychoudhury, P. title: Clinical performance characteristics of the Swift Normalase Amplicon Panel for sensitive recovery of SARS-CoV-2 genomes date: 2021-10-26 journal: nan DOI: 10.1101/2021.10.22.21265255 sha: e98e1afe223677552ac1c96b79525dbda0a1c439 doc_id: 258233 cord_uid: ps53t1px Amplicon-based sequencing methods have been central in characterizing the diversity, transmission and evolution of SARS-CoV-2, but need to be rigorously assessed for clinical utility. Here, we validated the Swift Biosciences SARS-CoV-2 Swift Normalase Amplicon Panels using remnant clinical specimens. High quality genomes meeting our established library and sequence quality criteria were recovered from positive specimens with a 95% limit of detection of 40.08 SARS-CoV-2 copies/PCR reaction. Breadth of genome recovery was evaluated across a range of Ct values (11.3 - 36.7, median 21.6). Out of 428 positive samples, 406 (94.9%) generated genomes with < 10% Ns, with a mean genome coverage of 13,545X/SD 8,382X. No genomes were recovered from PCR-negative specimens (n = 30), or from specimens positive for non-SARS-CoV-2 respiratory viruses (n = 20). Compared to whole-genome shotgun metagenomic sequencing (n = 14) or Sanger sequencing for the spike gene (n = 11), pairwise identity between consensus sequences was 100% in all cases, with highly concordant allele frequencies (R2 = 0.99) between Swift and shotgun libraries. When samples from different clades were mixed at varying ratios, expected variants were detected even in 1:99 mixtures. When deployed as a clinical test, 268 tests were performed in the first 23 weeks with a median turnaround time of 11 days, ordered primarily for outbreak investigations and infection control. Since the deposition of the first SARS-CoV-2 whole genome sequence (NC_045512.1) in 45 January 2020, over 4 million SARS-CoV-2 genomes have been deposited to public data 46 repositories, far exceeding any other human pathogen 1,2 . Such a feat has been made possible due 47 to advances in next-generation sequencing technologies that enable near real-time genomic 48 surveillance 3-9 . Viral whole-genome sequencing (WGS) of laboratory-confirmed SARS-CoV-2 49 isolates is frequently used in outbreak investigations, deployment of public health interventions, 50 development of vaccines and therapeutics, and evaluating vaccine and antiviral effectiveness 51 against emerging variants 4-6,10-15 . Specific SARS-CoV-2 variants have been associated with 52 higher viral loads, lower vaccine effectiveness, and worse outcomes such as mortality [16] [17] [18] [19] [20] [21] [22] [23] . 53 Notably, B.1.1.7 has been associated with increased disease severity, prolonged hospitalization, 54 and higher mortality risk 17, [19] [20] [21] [22] [23] [24] . Additionally, recent studies have shown poorer outcomes for 55 patients infected with variants B.1.351 and P.1 23,25 . In a clinical setting, identification of specific 56 viral mutations can aid in the selection of monoclonal therapies [26] [27] [28] [29] , and viral sequencing can be 57 used to monitor the accumulation of mutations as a result of long-term viral replication in 58 immunocompromised individuals 30 . As treatment regimens expand, validated WGS assays are 59 needed not only for genomic surveillance but also for high-quality, clinically actionable data 60 with rapid turnaround times. 61 Multiplexed amplicon sequencing methods have proven to be faster, more sensitive, and 62 more cost-effective than shotgun and capture-based approaches, enabling genome recovery 63 across a wide range of viral loads 31,32 . We previously tested one such panel from Swift 64 Biosciences and demonstrated genome recovery up to a Ct of 36 across a broad range of 65 isolates 33 . Designed against the SARS-CoV-2 Wuhan-Hu-1 complete genome (NC_045512.2), 66 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. validation of an NGS-based assay for WGS of SARS-CoV-2 to our knowledge 34,35 . Using 79 clinical specimens, we evaluated the analytical sensitivity, analytical specificity, the limit of 80 detection (LOD), accuracy, and precision (reproducibility and repeatability) of the assay, 81 establishing acceptance criteria for sequencing libraries and output genomes. This assay is now 82 available as a clinically orderable test with results returned to physicians to aid in disease 83 management and treatment. It has been used in multiple vaccine trials, research studies, 84 validation of other NGS-based assays, and in sequencing SARS-CoV-2 for public health 85 surveillance and outbreak investigation 6,10,36-40 . 86 Performance evaluation 89 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) We used existing FDA guidelines for designing, developing, and establishing the analytical 90 validity of NGS-based tests for the diagnosis of suspected germline diseases and development of 91 antivirals to clinically validate a multiplex amplicon sequencing method for WGS of SARS-92 CoV-2 (summarized in Supplementary Figure 1) Laboratory-confirmed specimens used in this study came from nasal or nasopharyngeal 108 swabs collected in either PBS or viral transport media that had >500 µL volume remaining. This 109 included SARS-CoV-2 positive specimens (n = 428), specimens negative for both SARS-CoV-2 110 and other respiratory viruses (n = 30), and specimens positive only for other respiratory viruses 111 (n = 20). Water was used as a negative control and previously confirmed and sequenced SARS-112 CoV-2 positive specimens were used as positive controls. 113 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 26, 2021. interpretation includes information about variants of concern/variants of interest (VOC/VOI) and 226 any known phenotypic effects associated with specific mutations such as increased 227 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 ) were prepared for each dilution with target 255 concentrations ranging from 500 copies/reaction to 5 copies/reaction. The concentrations of the 256 prepared dilutions were then verified by qRT-PCR and measured concentrations ranged from 257 698.0 to 7.8 copies/reaction. At concentrations of 82 copies/reaction and higher, high-quality 258 genomes were recovered in 100% of attempted replicates (n = 4 to 20, Table 1 ). The lowest 259 concentration at which acceptable genomes were recovered 95% of the time was defined as the 260 limit of detection (LOD) and determined by Probit analysis to be 40.08 copies/reaction ( . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3) . 286 Of the 30 samples that were PCR-negative for SARS-CoV-2, 17 did not meet quality 287 control criteria for successfully amplification during library preparation and were not taken 288 forward for sequencing. Of the remaining 13 sequenced samples, the number of mapped reads 289 ranged between 0 and 5271, representing < 0.5% of post-trimmed reads. No genomes were 290 recovered from any of these samples (Supplementary Table 4 ). 291 292 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 26, 2021. Table 6 ). Pairwise sequence identity between shotgun and Swift sequences 332 was 100% for all 14 sample pairs. For all single nucleotide variants identified at 1% or higher, 333 allele frequencies were highly concordant between Swift and mNGS libraries ( Miseq (Supplementary Figures 4, 5, 6) . 361 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We evaluated the performance of our data processing pipeline using CDC benchmark datasets of 368 samples confirmed to be VOC/VOI (n = 16 and non-VOC/VOI (n = 39) sequences. The number 369 A B . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Table 7) . After processing through our bioinformatic pipeline, consensus 371 genomes with < 10% Ns were obtained for all samples, with mean genome coverage between 372 159x -28,122x (median 2,598x), and mean spike gene coverage between 138x -22,099x 373 (median 1,954x). Pango and Nextclade lineages were compared for consensus sequences 374 generated by our pipeline against benchmark deposited consensus genomes. Lineages agreed in 375 16/16 VOC/VOI samples and 37/39 non-VOC/VOI samples. In the two non-VOC samples 376 where the lineages did not agree, the discrepancy was found to be due to mixed populations 377 being reported using IUPAC ambiguities in the benchmark set vs. the majority consensus base 378 being reported by TAYLOR. After masking ambiguous sites, consensus sequences in these 379 discrepant samples showed 100% pairwise identity. Semi-annual proficiency testing was performed via a sample exchange with a peer 390 CLIA/CAP-certified laboratory in which six blinded specimens were exchanged and sequenced. 391 Unblinding was performed following the completion of the study to compare the strains 392 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Given the wide range of viral loads among SARS-CoV-2 specimens, it can be 418 challenging to optimize multiplex amplicon panels to simultaneously achieve high sensitivity 419 and evenness of genome coverage. We found the manufacturer recommended settings to be 420 adequate for genome recovery across the range of viral loads we see in a majority of clinical 421 specimens. At very low viral loads, the high background of non-viral RNA can make genome 422 recovery challenging. In addition, the Swift SNAP protocol includes an optional proprietary 423 enzymatic normalization (Normalase) step, which results in equimolar pools with even coverage 424 across samples and amplicons. This allows for batching of samples with minimal sample 425 reorganization. While additional cycles of amplification may help stretch analytical sensitivity, 426 this can result in an accumulation of primer dimers that can affect overall run quality and may 427 amplify trace contaminants 54 . 428 One of the limitations of short-read sequencing using reference-based approaches is the 429 reduced ability to identify large structural variants, long indels, and tandem duplicates. Long 430 deletions often manifest as low coverage regions masked with ambiguous bases (Ns) and require 431 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 26, 2021. ; https://doi.org/10.1101/2021.10.22.21265255 doi: medRxiv preprint Jumping a Moving Train: SARS-CoV-2 Evolution in Real Rapid, Sensitive, Full-Genome Sequencing of Severe Acute 457 Respiratory Syndrome Coronavirus 2. Emerging infectious diseases 26 Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in 460 the United States Genomic surveillance reveals multiple introductions of SARS-CoV-2 into 462 Cryptic transmission of SARS-CoV-2 in Washington state Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus CoV-2 variant 501Y.V2 into the UK. The Journal of infection Genomic epidemiology identifies emergence and rapid 471 transmission of SARS-CoV-2 B.1.1.7 in the United States SARS-CoV-2 476 genomic variations associated with mortality rate of COVID-19 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the 481 mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 483 and B.1.351 variants and severe COVID-19 disease in Qatar Effectiveness of COVID-19 vaccines against variants Genomic characteristics and clinical effect of the emergent SARS-489 UK: a whole-genome sequencing and hospital-based 490 cohort study SARS-CoV-2 viral load is associated with increased disease severity 493 and mortality Viral loads in clinical specimens and SARS manifestations Predicting Infectivity: Comparing Four PCR-based Assays to Detect 563 CoV-2 in Clinical Samples Kinetics and isotype assessment of antibodies targeting the spike 566 protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in 567 COVID-19 patients as a function of age, biological sex and disease severity Comparative Performance of SARS-CoV-2 Detection Assays Using Seven 570 Different Primer-Probe Sets and One Assay Kit Rapid Metagenomic Next-Generation Sequencing during an Investigation 573 of Hospital-Acquired Human Parainfluenza Virus 3 Infections Metagenomic Analysis Reveals Clinical SARS-CoV-2 Infection and 576 Bacterial or Viral Superinfection and Colonization Twelve years of SAMtools and BCFtools Core Team. R: A language and environment for statistical computing. R Foundation for 580 Next generation sequencing of SARS-CoV-2 genomes: challenges, 584 applications and opportunities Improvements to the ARTIC multiplex PCR method for SARS genome sequencing using nanopore Disentangling primer 590 interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR Identification of multiple large deletions in ORF7a resulting in in-frame 593 gene fusions in clinical SARS-CoV-2 isolates